• Explore /
  • Poster
  • / Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).

Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).

Abstract Poster

Authors

null

Yoshiyuki Yamamoto

University of Tsukuba, Tsukuba, Japan

Yoshiyuki Yamamoto , Wataru Okamoto , Akitaka Makiyama , Kohei Shitara , Tadamichi Denda , Takashi Ogura , Yasuyuki Nakano , Tomohiro Nishina , Masato Komoda , Hiroki Hara , Yukinori Ozaki , HIsato Kawakami , Narikazu Boku , Ichinosuke Hyodo , Kentaro Yamazaki , Shuichi Hironaka , Kazuko Sakai , Takeharu Yamanaka , Kei Muro , Kazuto Nishio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

UMIN000012442

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 670)

DOI

10.1200/JCO.2018.36.4_suppl.670

Abstract #

670

Poster Bd #

F7

Abstract Disclosures

Similar Posters

First Author: Kathrin Heinrich

First Author: Thomas Seufferlein

Poster

2020 Gastrointestinal Cancers Symposium

Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.

Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.

First Author: Mitsukuni Suenaga

First Author: Wataru Okamoto